These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 22077794)
41. Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine. Schallreuter KU; Wood JM; Mensing H; Breitbart EW Cancer Chemother Pharmacol; 1991; 29(2):167-71. PubMed ID: 1760862 [TBL] [Abstract][Full Text] [Related]
42. Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. Seeber A; Binder M; Steiner A; Wolff K; Pehamberger H Eur J Cancer; 1998 Dec; 34(13):2129-31. PubMed ID: 10070323 [TBL] [Abstract][Full Text] [Related]
43. Phase II trial of fotemustine in patients with metastatic malignant melanoma. Falkson CI; Falkson G; Falkson HC Invest New Drugs; 1994; 12(3):251-4. PubMed ID: 7896545 [TBL] [Abstract][Full Text] [Related]
44. Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma. Göring HD; Zierner A; Kröning Y; Trebing D; Kämpgen E; Bröcker EB Melanoma Res; 1998 Aug; 8(4):379. PubMed ID: 9764815 [No Abstract] [Full Text] [Related]
45. [Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]. Mornex F; Thomas L; Mohr P; Hauschild A; Delaunay MM; Lesimple T; Tilgen W; Nguyen BB; Guillot B; Ulrich J; Bourdin S; Mousseau M; Cupissol D; Bonneterre J; de Gislain C; Bensadoun JR; Clavel M Cancer Radiother; 2003 Feb; 7(1):1-8. PubMed ID: 12648711 [TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients. Mangiacavalli S; Pica G; Varettoni M; Lazzarino M; Corso A Eur J Haematol; 2009 Mar; 82(3):240-1. PubMed ID: 19018860 [No Abstract] [Full Text] [Related]
47. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. Leyvraz S; Spataro V; Bauer J; Pampallona S; Salmon R; Dorval T; Meuli R; Gillet M; Lejeune F; Zografos L J Clin Oncol; 1997 Jul; 15(7):2589-95. PubMed ID: 9215829 [TBL] [Abstract][Full Text] [Related]
48. Fotemustine with or without dacarbazine for brain metastases of malignant melanoma. Merimsky O; Inbar M; Reider-Groswasser I; Chaitchik S Eur J Cancer; 1991; 27(8):1066. PubMed ID: 1832900 [No Abstract] [Full Text] [Related]
49. Complete remission seven years after treatment for metastatic malignant melanoma. Petit T; Borel C; Rixe O; Avril MF; Monnier A; Giroux B; Weil M; Khayat D Cancer; 1996 Mar; 77(5):900-2. PubMed ID: 8608481 [TBL] [Abstract][Full Text] [Related]
50. [Experience with use of mustoforan at the Clinical Oncological Dispensary of the Republic of Tatarstan]. Karpenko LG Vopr Onkol; 2005; 51(3):388-90. PubMed ID: 16279110 [No Abstract] [Full Text] [Related]
51. [Effectiveness and safety of combined mustoforan, cisplatin and tamoxifen for disseminated cutaneous melanoma (results of the IC4-10036-46-RU trial)]. Konstantinova MM; Gershanovich ML; Akimov MA; Nosov DA; Bogdanova NV Vopr Onkol; 2005; 51(5):550-7. PubMed ID: 16756009 [TBL] [Abstract][Full Text] [Related]
52. Isolated limb perfusion in locally advanced cutaneous melanoma. Rossi CR; Foletto M; Pilati P; Mocellin S; Lise M Semin Oncol; 2002 Aug; 29(4):400-9. PubMed ID: 12170443 [TBL] [Abstract][Full Text] [Related]
53. Phase I study of fotemustine in pediatric patients with refractory brain tumors. Hargrave DR; Bouffet E; Gammon J; Tariq N; Grant RM; Baruchel S Cancer; 2002 Sep; 95(6):1294-301. PubMed ID: 12216098 [TBL] [Abstract][Full Text] [Related]
54. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. Rixe O; Borel C; Paraiso D; Benhammouda A; Petit T; Antoine E; Bizzari JP; Auclerc G; Soubrane C; Weil M Melanoma Res; 1995 Dec; 5(6):419-24. PubMed ID: 8589616 [TBL] [Abstract][Full Text] [Related]
55. Phase I-II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer. Le Cesne A; Chabot G; Bérille J; Lucas C; Baud M; Gouyette A; Marty M; Le Chevalier T Lung Cancer; 1995 Aug; 13(1):69-78. PubMed ID: 8528641 [TBL] [Abstract][Full Text] [Related]
56. Prevention of hepatotoxicity but loss of antimelanoma effect with combined fotemustine and anti-oxidant treatment. Webster GJ; Kurtovic J; Singh-Grewal I; Friedlander M; Riordan SM Intern Med J; 2004 May; 34(5):298-9. PubMed ID: 15151681 [No Abstract] [Full Text] [Related]
57. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients. Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R; Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411 [TBL] [Abstract][Full Text] [Related]